Floatz logo

Depakine

Treatment Resistant Bipolar Disorder

Dr. Stavroula RakitziPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

66 Active assets in the Treatment Resistant Bipolar Disorder cohort.

Asset / SponsorPhaseRating
Asenapine
Dr. Stavroula Rakitzi
Phase 4BBB
LAMOTRIGINE
Johns Hopkins University
Phase 4BBB
Paroxetine
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Phase 4BBB
LITHIUM, ELEMENTAL
University of Aarhus
Phase 4BBB
Seroquel®
First Affiliated Hospital of Zhejiang University
Phase 4BBB

View all 50 →

Same molecule, other indications

Depakine is also rated in:

Bipolar DisorderDormant
B
Indicative ·
63 / 100
View asset →
treatment-refractory schizophreniaDormant
B
Indicative ·
62 / 100
View asset →
Wolfram syndromeDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →